Iqvia price target raised to $240 from $210 at HSBC

HSBC analyst Sidharth Sahoo raised the firm's price target on Iqvia to $240 from $210 and keeps a Buy rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative outperformance potential for the second half of the year, noting that the Therapeutics space offering "attractive risk weighted returns," Tools "might be the best way to play a cyclical rally," and that MedTech is "cheap."